ELTX Stock Summary and Trading Ideas (Elicio Therapeutics | NASDAQ:ELTX)

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Elicio Therapeutics trades on the NASDAQ stock market under the symbol ELTX.

As of January 8, 2026, ELTX stock price declined to $8.24 with 145,157 million shares trading.

ELTX has a beta of 1.00, meaning it tends to be less sensitive to market movements. ELTX has a correlation of 0.06 to the broad based SPY ETF.

ELTX has a market cap of $142.21 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that ELTX belongs to (by Net Assets): VTI, VXF, IWC.

ELTX has outperformed the market in the last year with a price return of +36.7% while the SPY ETF gained +18.4%. However, in the short term, ELTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -23.6% vs +3.3% return in SPY. But in the last 2 weeks, ELTX shares have fared better than the market returning +0.6% compared to SPY -0.1%.

ELTX support price is $8.02 and resistance is $8.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELTX shares will trade within this expected range on the day.